AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02464046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
Study NCT03598257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03598257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03598257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03598257 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03598257 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03598257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study NCT03598257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary study
Study NCT02077777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: Mesalazine cpr 800 mg t.i.d. for 3 months
Study NCT01798901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDAC inhibitor AR-42
Description: Given PO
Study NCT01798901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT01798901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01798901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02499783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: subcutaneous injections of placebo
Study NCT02437266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular mobilization
Study NCT01264900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
Study NCT01264900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
Study NCT02284984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab with belimumab
Description: Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
Study NCT03131778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: liver resections for colorectal liver metastases
Study NCT03131778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: liver resections for colorectal liver metastases
Study NCT00935363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: single oral dose
Study NCT00935363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide + fluconazole
Description: single dose oral glyburide single dose iv fluconazole
Study NCT00935363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide + rifampin
Description: single dose oral glyburide single dose iv rifampin
Study NCT00935363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide + fluconazole + rifampin
Description: single dose oral glyburide single dose iv fluconazole single dose iv rifampin
Study NCT02523248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillectomy
Description: Tonsillectomy with cold steel
Study NCT02523248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uvulopalatopharyngoplasty
Description: Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
Study NCT00373152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
Study NCT00373152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
Study NCT00373152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
Study NCT00373152 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gadopentetate dimeglumine
Description: Injected at baseline MRI and post radiofrequency ablation MRI.
Study NCT02018185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A non-invasive method for brain stimulation
Study NCT02018185 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham stimulation of the brain.
Study NCT01936805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
Study NCT03050554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
Study NCT03133182 — intervention group
Intervention type: DRUG
Intervention: Polypharmacy
Description: Patients who are taking >=5 unique prescription drugs in the 3 months prior to surgery
Study NCT03050554 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
Study NCT01816204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist assisted online treatment
Description: 7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
Study NCT01816204 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: face-to-face individual therapy
Description: weekly individual counseling as usual.
Study NCT04216849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
Study NCT00555971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subjects randomized to Omalizumab prior to aspirin desensitization
Study NCT00555971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomized to Placebo prior to aspirin desensitization
Study NCT01412320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: dissolved in water twice daily
Study NCT02667054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RX0041 4%
Description: Anesthetic
Study NCT02667054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT02667054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RX0041 8%
Description: Anesthetic
Study NCT04216849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline solution containing human serum albumin will be infused to the control group
Study NCT00512850 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folic acid
Description: Intervention group 1g folic acid per day
Study NCT03528772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: application of minoxidil forte 5% gel three time per day on the anus for four weeks
Study NCT03150433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral symptom management
Description: Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
Study NCT03150433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sickle cell disease management
Description: Individual sessions focused on understanding and managing sickle cell disease
Study NCT00512850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: One placebo pill per day
Study NCT04644588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
Description: Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
Study NCT03463473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/kg Q3W MSB2311 Injection
Description: An intravenous infusion with concentration from 3 mg/kg (Q3W)
Study NCT03463473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg Q3W MSB2311 Injection
Description: An intravenous infusion with concentration from 10 mg/kg (Q3W)
Study NCT03463473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg/kg Q3W MSB2311 Injection
Description: An intravenous infusion with concentration from 20 mg/kg (Q3W)
Study NCT03463473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg Q2W MSB2311 Injection
Description: An intravenous infusion with concentration from 10 mg/kg (Q2W)
Study NCT03967171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: before uterine incision oxytocin
Description: blood loss during elective cesarean section
Study NCT03967171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: after clamping the umbilical cord oxytocin
Description: blood loss during elective cesarean section
Study NCT00332579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: daily
Study NCT00332579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study NCT00862368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAM
Description: Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
Study NCT00862368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAM
Description: Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
Study NCT03528772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl trinitrate
Description: application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
Study NCT01008592 — intervention group
Intervention type: DRUG
Intervention: levocetirizine or placebo
Description: oral administration, single tablet, 5 mg.
Study NCT00862368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAM-Enhanced/Asthma Counseling Phone Calls
Description: PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
Study NCT00862368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-Up Phone Calls - Child Wellness Topic
Description: Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
Study NCT04447235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
Study NCT04447235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
Study NCT04447235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
Study NCT01336712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplant
Description: Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m\^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4
Study NCT03520296 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire evaluating well-being in relation to diet and nutrition
Study NCT01021046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DALK using GCCT
Description: Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
Study NCT01021046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DALK using FCT
Description: Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
Study NCT02433054 — intervention group
Intervention type: DEVICE
Intervention: CE-certified dedicated venous stents
Description: Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
Study NCT04271735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen
Description: Participants will take two capsules of nicotinamide riboside (NR) by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.
Study NCT04271735 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to match the active supplement. Participants will take two capsules, twice daily for a total of 4 weeks.
Study NCT02494180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fentanyl
Description: arm A receiving iv fentanyl
Study NCT02494180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pethidine
Description: arm B receiving iv pethidine
Study NCT02494180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diazepam
Description: arm B receiving iv diazepam
Study NCT02494180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: arm A receiving iv midazolam
Study NCT03202524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Description: FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.
Study NCT03202524 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care
Study NCT02629354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study NCT02629354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT02629354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT02829294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E002 - cerumen removal aid
Description: topical treatment
Study NCT02802774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plaster Splint
Description: The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
Study NCT02802774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Velcro Brace
Description: The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
Study NCT02802774 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft Dressing
Description: Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
Study NCT01324674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bach´s Flower Remedy
Description: The subjects will have 4 drops 4 times per day, for approximately 8 months.
Study NCT01324674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
Study NCT00682682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality video distraction
Description: Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game.
Study NCT00682682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality video game
Description: Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World
Study NCT02640053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Applied topically
Study NCT02640053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02640053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT02640053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02640053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02640053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02640053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03429517 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lipogram
Description: liporgram samples
Study NCT04105426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidants
Description: one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
Study NCT04105426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one placebo tablet three times per day for 3 months.
Study NCT04912193 — intervention group
Intervention type: DRUG
Intervention: Antithrombin III
Description: In liver transplant recipients with baseline antithrombin III levels lower than 50%, exogenous Antithrombin III was administrated during the anhepatic phase of the liver transplant surgery.
Study NCT04289675 — intervention group
Intervention type: DRUG
Intervention: Interferon-Beta
Description: Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.